DUPCHECKTM
IS AVAILABLE TO PHARMACEUTICAL COMPANIES,
ACADEMIC INVESTIGATORS AND QUALIFIED RESEARCH SITES.
   
       
About DupCheck

DupCheck is a web-based tool used globally to screen for duplicate patients in clinical trials across studies, sponsors and therapeutic areas. Duplicate enrollment harms both patients and studies.In many therapeutic areas even a small number of duplicate patients can lead to a negative or failed trial.  In addition enrolling duplicate patients can result in a misattributed serious adverse event.

DupCheck is part of NEWMEDS an international consortium of scientists that has launched one of the largest ever research academic-industry collaboration projects to find new methods for the development of drugs.  NEWMEDS brings together top scientists from academic institutions with a wide range of expertise, and partners them with nearly all major biopharmaceutical companies.  NEWMEDS ultimate goal is to develop new approaches for shorter and more efficient trials of new medications. 

DupCheck provides sites and sponsors with real time information on attempted duplicate enrollment at time of screening. DupCheck can also screen for previous participation in a trial of investigational drug. 

DupCheck can be linked to existing electronic data capture systems—eliminating additional data entry—and run in the background, analogues to an anti-virus.  

Integration

DupCheck is available for integration with: 

  • Trident IRT by Bioclinica   

    bioclinica.com/news-events/news-releases/bioclinica-announces-new-ehealth-app-xchange-partners-driving-industry

  • Foundry Health, ClinSpark, Web-base phase 1 eSource/EDC system supporting traditional browsers and mobile devices. 

  • Y-Prime IRT and eCOA systems.
  • Veracity VLIRT system
  • Suvoda IRT/IWRS 
  • AG Mednet
  • MedSciNet EDC and IVRS. MedSciNet specializes in designing and developing web applications and online database systems for medical research. MedSciNet is an international company with its roots at the Karolinska Institute (Sweden), specializing in web applications and online database systems for clinical trials, medical registries and biobanks. 
  • Target e*CRF, the fully integrated paperless clinical trial solution from Target Health 
  • NEFORM by NESS, the only eSource, mobile, data capture system, that collects clinical eCRF, site/home ePRO and rater evaluation data on Apple IOS, Android™ and Windows tablets, smartphones and PCs with or without an internet connection.

DupCheck provides sponsor with one click real time data on screening by site. 

DupCheck is HIPAA and European Data Protection Regulation compliant.  No identifiable patient or sponsor data is transmitted, stored or shared.  DupCheck was given a favorable Qualification Advice review by the European Medicines Agency and the FDA has stated that DupChecking is advisable.

DupCheck is an ACRES ally


For a link to a 6 minute video demonstrating DupCheck or for more information, sponsors, investigators and regulators please contact us at: Contact@DupCheck.org


Core Team


Jonathan rabinowitz

Founding Director

Jonathan Rabinowitz, PhD is the founding director of DupCheck.  He is the Elie Wiesel Professor at Bar Ilan University and a visiting professor at Mount Sinai School of Medicine in New York.  His research focuses on improving efficiency of clinical trials.  He has over 25 years of experience in managing and analyzing large data sets and in developing and implementing statistical algorithms in pharmaceutical, services and epidemiological datasets.  He is the academic lead of the Advanced Data Analysis Techniques group at IMI/EFPIA sponsored NEMWEDS, one of the largest ever research academic-industry collaboration projects directed at finding new methods for drug development.  He did doctoral training in Statistics at Bar Ilan University and in Social Welfare at Yeshiva University.  He serves on advisory groups at FDA and EMA.  He is a member of the American College of Neuropsychopharmacology.  He is on the Executive Committee of International Society for CNS Clinical Trials and Methodology and also serves as co-chair of the working group on consistency in measurement.  He has served as a member of the DIA Scientific Working Group on Missing Data in Clinical Trials.  He has over 170 scientific publications. 


David Feigenbaum

Strategic Planning

David Feigenbaum, DBA holds a doctorate in Decision Sciences from the Graduate School of Management at Kent State University and a BS and MBA from Case Western Reserve University.  He has served in various senior management positions at American Greetings, Chessie Systems and Arthur D. Little and has worked as an independent consultant.  He has served as Adjunct Associate Professor at the University of Maryland College Park.

Chief Technology Officer

Mr. Alexey Abraham has over 20 years of software development experience. Among them 8 years in product and project management of complex software projects in different countries.
The companies, he has worked for include: Intel, Orange UK, Comverse, NOVA, Matrix, Zoral Labs, Gat Systems, FinalView, Towndwarf Co., Control&Robotics Solutions. Alexey has vast experience in server side and front end development, computer security, complex web systems, mobile development for different platforms, low level programming for Windows & Linux, surveilance and image recognition systems, banking.
These are projects now running on more than 200 Telephone Stations worldwide, 3 Intel FABs, several Internet Providers worldwide and 2 major banks.

Gregory Kogan

Information Technology (IT) Team Leader

Gregory Kogan, has over 18 years of software development and project management experience.  He held developer, team and project leader positions at Nareos, Samsung Telecom Research Israel, Harel Insurance Company, First International Bank of Israel and IBM Israel Software Lab.  He has a B.Sc. in Computer Science from Bar Ilan University.  Mr. Kogan has deep pockets of expertise in database architecture, administration, design, web development and system security.

Legal Services

Gross, Kleinhendler, Hodak, Halevy, Greenberg & Co.

www.gkh-law.com

   
   
efpia newmeds imi eu acres